The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2408-2412

  Shima, Yoshihito ^a   Kuwahara, Yusuke ^a   Murota, Hiroyuki ^a   Kitaba, Shun ^a   Kawai, Mari ^a   Hirano, Toru ^a   Arimitsu, Junsuke ^a   Narazaki, Masashi ^a   Hagihara, Keisuke ^a   Ogata, Atsushi ^a   Katayama, Ichiro ^a   Kawase, Ichiro ^a   Kishimoto, Tadamitsu ^b   Tanaka, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Anti IL 6 receptor antibody; Interleukin 6; Scleroderma; Skin score; Systemic sclerosis; Tocilizumab; Vesmeter

Indexed keywords

ANTINUCLEAR ANTIBODY; CARBON MONOXIDE; CHYMOSIN; COLLAGEN FIBER; CREATININE; CYCLOSPORIN A; INTERLEUKIN 6; PREDNISOLONE; PSORALEN; TELMISARTAN; TOCILIZUMAB;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CUTANEOUS PARAMETERS; DISEASE COURSE; DRUG EFFECT; DRUG RESEARCH; DYSPNEA; ESOPHAGUS DILATATION; FEMALE; FORCED EXPIRATORY VOLUME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; JOINT SWELLING; KIDNEY FUNCTION; LUNG FIBROSIS; MALE; OCCULT BLOOD; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEINURIA; SCLERODERMA; SKIN BIOPSY; SKIN SOFTNESS; SPIROMETRY; SYSTEMIC SCLEROSIS; URINALYSIS; URINE VOLUME;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 78049421175     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq275     Document Type: Article

References (14)

1. Kowal-Bielecka O, Landewe R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2008;68:620-8.
2. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308-13.
3. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
4. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. Kuwahara Y, Shima Y, Shirayama D et al. Quantification of hardness, elasticity and viscosity of the skin of patients with systemic sclerosis using a novel sensing device (Vesmeter): a proposal for a new outcome measurement procedure. Rheumatology 2008;47:1018-24.
7. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990;33:1256-63.
8. Pool JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991;4: 27-31.
9. Sappino AP, Masouye I, Saurat JH, Gabbiani G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol 1990;137:585-91.
10. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006;54:3566-60.
11. Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994;73:493-6.
12. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
13. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253-60.
14. Crestani B, Seta N, De Bandt M et al. Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994;149:1260-5.